We review the clinical, humanistic, and economic value of pembrolizumab monotherapy and combination therapies in the treatment of patients with breast and gynecologic cancers.

Recent clinical trials have established pembrolizumab regimens as a standard of care treatment for triple-negative breast cancer, cervical cancer, and endometrial cancer.

Patient-reported outcomes, cost-effectiveness analysis, and real-world evidence support the clinical data.

Several ongoing phase 3 studies are evaluating pembrolizumab regimens in patients with triple-negative breast cancer (1 trial), HR+/HER2− breast cancer (2 trials), endometrial cancer (3 trials), cervical cancer (1 trial), and ovarian cancer (3 trials), with the goal of improving the lives of patients and potentially providing a cure for patients with early-stage disease.

Results from these ongoing studies of pembrolizumab will expand the current understanding of its use in breast and gynecologic cancers.